about
Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical AspectsPhospholipid in the hexagonal II phase is immunogenic: evidence for immunorecognition of nonbilayer lipid phases in vivoLupus anticoagulants in systemic lupus erythematosus: prevalence and clinical associations.Laboratory evaluation of a bleeding patient.Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant.The lupus anticoagulant, pulmonary thromboembolism, and fatal pulmonary hypertension.Budd-Chiari syndrome as the major thrombotic complication of systemic lupus erythematosus with the lupus anticoagulant.Haemostatic factors associated with vascular thrombosis in patients with systemic lupus erythematosus and the lupus anticoagulant.Intracardiac thrombosis, phospholipid antibodies, and two-chambered right ventricle.Acquired heparinlike anticoagulant in a patient with metastatic breast carcinomaIsolation and study of an acquired inhibitor of human coagulation factor V.Thrombosis in systemic lupus erythematosus: a French collaborative studyIndeterminate lupus anticoagulant results: Prevalence and clinical significance.Antiphospholipid syndrome: laboratory testing and diagnostic strategies.Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulantMethods for detecting lupus anticoagulants and their relation to thrombosis and miscarriage in patients with systemic lupus erythematosusTransient lupus anticoagulant and fansidar therapyCoagulation inhibitor in hypothyroidism.
P2860
Q27023280-EB10C703-197E-40D3-ADDD-BE1412B111D2Q28329381-6FD00830-1C12-4D03-85E4-BF3E18EC3C20Q33393751-FC5CF442-B940-4821-A3D2-CF84C7F1617BQ33427841-397C8B99-8AF5-4CA1-A18B-C5821294271CQ33478061-EDDAEA94-B87D-4AF3-B45A-2F89E617C04CQ33555478-0AFC1FB0-7670-46AF-AECE-A4996685AB4BQ33556669-78E76E91-F050-4771-B9DA-58919FDC4D59Q33563788-4CAC0E10-4440-44DB-970C-1DA2F494E913Q33999868-829E8BB6-3A27-4229-80A3-9E0071AF1904Q34193126-B1866E5A-F699-4EB6-B0CD-73F609DFE030Q34520485-801DCFDC-1D20-4A74-80FE-D460A2D4B27FQ35626838-20CA369E-3672-4D3E-A194-6C324689D996Q35676030-56B4BDA8-9225-479A-A4B1-4169C8BA5EB3Q36844544-4E8A0848-8ED7-4175-A183-F559BA5CBF7CQ37027827-4CD06E88-4EE2-4E4E-A75F-61B6B7380A18Q37111561-697FCC2D-80AA-41F3-8830-D5F99EAB5DEFQ39018957-8540EEA5-4AE5-4BB6-B60F-8C2B5C9D844AQ41780159-17FA68D3-8000-4C0A-9DA1-A2EFBAE14CE7
P2860
description
1972 nî lūn-bûn
@nan
1972 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1972 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1972年の論文
@ja
1972年論文
@yue
1972年論文
@zh-hant
1972年論文
@zh-hk
1972年論文
@zh-mo
1972年論文
@zh-tw
1972年论文
@wuu
name
Acquired inhibitors of blood coagulation.
@ast
Acquired inhibitors of blood coagulation.
@en
Acquired inhibitors of blood coagulation.
@nl
type
label
Acquired inhibitors of blood coagulation.
@ast
Acquired inhibitors of blood coagulation.
@en
Acquired inhibitors of blood coagulation.
@nl
prefLabel
Acquired inhibitors of blood coagulation.
@ast
Acquired inhibitors of blood coagulation.
@en
Acquired inhibitors of blood coagulation.
@nl
P1476
Acquired inhibitors of blood coagulation
@en
P2093
Feinstein DI
Rapaport SI
P577
1972-01-01T00:00:00Z